-
More Patients Participating in Cancer ResearchA higher proportion of cancer patients are enrolling in research studies than previously thought, but many patients lack the access needed to participate.
by Kyle Bagenstose
-
A Treatment That Came Just in TimeCancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma.
by Laurie Adami
-
Immunotherapy Indications WithdrawnIn recent months, drugmakers have announced they are withdrawing indications for four immune checkpoint inhibitors in consultation with the Food and Drug Administration. What does this mean for patients who are taking these drugs?
by Anna Goshua
-
Testing COVID-19 Treatments for Patients With Cancer: An Ongoing NeedResearchers are studying the effectiveness of drugs for treating COVID-19 in cancer patients who have been infected with the coronavirus.
by Marcus A. Banks
-
Immunotherapy Options for Breast CancerTwo immune checkpoint inhibitors are now approved for treatment of some people with advanced breast cancer, but trial results have raised some questions.
by Anna Goshua
-
Liquid Biopsies May Ease Enrollment in Clinical TrialsA study shows that a blood test for gastrointestinal tumor mutations gave results in a third of the time needed for solid tissue testing. Patients who received the blood test were more likely to enroll in clinical trials.
by Emma Yasinski
-
What Is Tumor Mutational Burden?The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.
by Anna Azvolinsky
-
Targeted Therapy for Early-Stage Lung Cancer?A trial of the targeted therapy Tagrisso (osimertinib) for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion.
by Ashley P. Taylor
-
Trials InterruptedCOVID-19 slowed or stopped enrollment in some cancer clinical trials.
by Kate Yandell
-
Facing Cancer and a Pandemic at the Same TimeCancer patients and their families share stories of fear, love and uncertainty as they find new ways to support each other.
by Jen Tota McGivney
Challenges in developing and studying treatments call for new ways of thinking about cancer research.
by Eric Fitzsimmons
Treating Smoldering Multiple MyelomaA monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
-
AACR IO: Revolutionizing Treatment through ImmunotherapyThe AACR’s immuno-oncology meeting brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
